Cladribine is a safe and effective treatment for highly active relapsing-remitting multiple sclerosis

被引：0
|
作者：
Suslak, T. [1 ]
Macdougall, N. [2 ]
Murray, L. [1 ]
机构：
[1] NHSGGC, Glasgow, Lanark, Scotland
[2] NHSGGC, NHSL, Glasgow, Lanark, Scotland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0309
引用
收藏
页码：269 / 269
页数：1
相关论文
共 50 条
  • [1] Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis
    Comi, Giancarlo
    Hartung, Hans-Peter
    Kurukulasuriya, Nuwan C.
    Greenberg, Steven J.
    Scaramozza, Matthew
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (01) : 123 - 136
  • [2] Is interferon effective and safe for relapsing-remitting multiple sclerosis?
    Filippini, G
    Incorvaia, B
    NEUROEPIDEMIOLOGY, 2002, 21 (06) : 310 - 310
  • [3] Cladribine TabletsIn Relapsing-Remitting Multiple Sclerosis
    Victoria J. Muir
    Greg L. Plosker
    CNS Drugs, 2011, 25 : 239 - 249
  • [4] An update on cladribine for relapsing-remitting multiple sclerosis
    Holmoy, Trygve
    Torkildsen, Oivind
    Myhr, Kjell-Morten
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (15) : 1627 - 1635
  • [5] Cladribine Tablets In Relapsing-Remitting Multiple Sclerosis
    Muir, Victoria J.
    Plosker, Greg L.
    CNS DRUGS, 2011, 25 (03) : 239 - 249
  • [6] Treatment with alemtuzumab after fingolimod in relapsing-remitting multiple sclerosis is effective and safe
    Alcala, C.
    Gascon, F.
    Perez-Miralles, F.
    Dominguez, J. A.
    Garcia Gil-Perotin, S.
    Casanova, B.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 274 - 274
  • [7] Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis
    Victoria J. Muir
    Greg L. Plosker
    CNS Drugs, 2020, 34 : 447 - 447
  • [8] Effectiveness of cladribine tablets in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study
    Habek, M.
    Brecl, G. Jakob
    Rajda, C.
    Adamec, I.
    Barun, B.
    Rok, A.
    Ledinek, A. Horvat
    Rot, U.
    Jazbec, S. Sega
    Gabelic, T.
    Klivenyi, P.
    Skoric, M. Krbot
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 894 - 894
  • [9] COST-CONSEQUENCE OF CLADRIBINE TABLETS FOR THE TREATMENT OF HIGHLY-ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) IN THE UK
    Miller, B.
    Russel-Szymczyk, M.
    Jensen, I. S.
    Shah, A.
    Alexopoulos, S. T.
    Herbert, A.
    McLean, T.
    Tundia, N.
    VALUE IN HEALTH, 2023, 26 (12) : S180 - S180
  • [10] Subcutaneously delivered natalizumab for the treatment of highly active relapsing-remitting multiple sclerosis
    Haluskova, S.
    Valis, M.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2022, 85 (03) : 206 - 212
12345